Auro Vaccines DNA priming / VesiculoVax™ boosting represents a significant advance over therapeutic approaches that use DNA vaccines alone to induce T-cell immune responses. DNA vaccines effectively prime T cells for rapid synergistic expansion upon VesiculoVax™ boosting into effector T cells that are uniquely suited to attacking virally infected cells and cancers. Auro Vaccines combines best-in-class DNA vaccines co-administered with human IL-12 (a natural “molecular adjuvant”) and delivery via electroporation to prime the immune system. Specifically, the Auro Vaccines DNA technology overcomes the poor immunogenicity of conventional DNA vaccines by integrating:
- Co-formulation of the DNA plasmids with bupivacaine, a small-molecule anesthetic that stabilizes pDNA vaccines by intercalating with pDNA helix and improving delivery into the target tissue.
- Co-formulating the immunogen-expressing DNA plasmids with a plasmid-expressing the potent molecular adjuvant IL-12, which directs responding T cells down the pathway to becoming T effector cells with the capacity to kill virally infected cells and cancer cells.
- Delivering DNA vaccine formulations via electroporation, which enhances vaccine entry into target cells.
Product Example:
Best-in-class PBS Vax™ therapeutic vaccines for chronic viral infectious diseases.
DNA priming followed by VesiculoVax™ boosting enables the development of next-generation therapeutic T cell vaccines that induce an enhanced and durable T cell-mediated immune response to mitigate disease caused by viruses such as HPV, HBV, HCV and HSV-2.